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The aim of this study was to visualize the tumor propagation and surrounding mucosal field in 
radiography-based 3D model for advanced stage HNSCC and combine it with HPV genotyping and 
miRNA expression characterization of the visualized area. 25 patients with T1-3 clinical stage HNSCC 
were enrolled in mapping biopsy sampling. Biopsy samples were evaluated for HPV positivity and miR-
21-5p, miR-143, miR-155, miR-221-5p expression in Digital Droplet PCR system. Significant miRNA 
expression differences of HPV positive tumor tissue biopsies were found for miR-21-5p, miR-143 and 
miR-221-5p compared to the HPV negative tumor biopsy series. Peritumoral mucosa showed patchy 
pattern alterations of miR-21-5p and miR-155 in HPV positive cases, while gradual change of miR-21-5p 
and miR-221-5p was seen in HPV negative tumors. In our study we found differences of the miRNA 
expression patterns among the HPV positive and negative tumorous tissues as well as the surrounding 
mucosal fields. The CT based 3D models of the cancer field and surrounding mucosal surface can be 
utilized to improve proper preoperative planning. Complex evaluation of HNSCC tissue organization 
field can elucidate the clinical and molecular differentiation of HPV positive and negative cases, and 
enhance effective organ saving therapeutic strategies.
In addition to the widely-known etiological factors including various chemical carcinogens and poor oral hygiene, 
the human papilloma viruses (HPV) are major risk factors in the development of head and neck squamous cell 
carcinomas (HNSCC)1. Oral HPV positivity and the number of viral-induced oropharyngeal tumors have signif-
icantly higher frequency in males2. In the oropharyngeal region the highest HPV positivity can be detected in the 
palatine tonsils. The HPV positivity ratio of these tumors can amount to 70% compared to the other sub regions3. 
The mucosal surface of lacunas and crypts constitute a strong conjunction between the epithelial mucosa and the 
lymphatic tissue underneath and is often revealed in the background of tonsillar predilection of HPV initiated car-
cinogenesis4. Clinical investigations have shown revealed remarkable differences between tumors induced by HPV 
and chemical carcinogenesis: HPV induced tumors particularly emerge at younger ages, and in many cases, the 
first clinical sign of the malignancy is the lymph node metastasis. The size of primary tumor is frequently small and 
thereby, it is difficult to explore in the early stage, however, later it often increases in tumor size compared with those 
HPV negative tumors in the same stage. HPV positive cancers respond much better to oncological and surgical ther-
apy, thus prognosis is generally, far more favorable5–8. Considering the differences from aspects of prognosis, behav-
ior and development, a separate TNM classification was released in 2017 for HPV positive oropharyngeal tumors9,10.
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Human papilloma Virus
HPV belongs to the family of Papillomaviridae and the HPV Reference Center has classified more than 120 types 
(Papillomavirus Episteme – NIH). The viral genome in this family is a circular, double-stranded DNA (deoxyri-
bonucleic acid). Regarding the most conserve sequence of the viral genome, which is the L1 open reading frame 
(ORF) region, the HPV types belong to seven taxonomical genera (alpha-, beta-, gamma-, mupa- and nupa- eta- 
and thetapapillomaviridae). Protein products translated from L1 and L2 ORFs constitute the viral capside, while 
E6 and E7 ORFs encode oncoproteins that modulate the viral transformation process. HPV infects the basal cells 
of the multilayer epithelium. The modification of the epithelial cell differentiation, through regulation of the cell 
cycle, results in the generation of the continuous reactivation of DNA replication and leads to the replication of 
the genome of the HPV virus11–14 Cutaneous and mucosal invasive types of the HPV can be distinguished, accord-
ingly. Based on oncological risk groups mucosal types can be assigned according to low, intermediate and high 
risk HPV. The identification of multiple viral infections is frequently observed and the resulting virulence might 
be influenced by the different genotypes. However interference between different HPV types and the impact on 
their virulence are events that have not been demonstrated yet. Due to the fact, that clinical observations about 
the behavior of the HPV positive oropharyngeal cancer differ so much from HPV negative HNSCC, a new TNM 
classification was needed to be introduced with a specific staging guideline. This statement is underlined by the 
The Cancer Genome Atlas (TCGA) publication on comparative molecular characteristics of the HPV positive 
and negative HNSCCs. The difference between the HPV associated and non-viral groups was clearly confirmed15. 
The TCGA study was not able to determine sufficient number of oncogenic mutation HNSCC that can drive the 
mechanisms of carcinogenesis; beside of this fact many epigenetical alterations were proved to characterize this 
cancer type. Linking to this concept, a recent publication of Masuda et al. stated that HNSCC is strongly linked 
to changes in epigenetic regulatory16. miRNAs as translator molecules between the environmental exposures and 
genomic regulation might reflect the carcinogenic process through their expression profile changes.
Cancer Field
Chemical and viral carcinogens constitute a genetically and epigenetically modified field in the intact cells of the 
mucosal surface as the first step of carcinogenesis. The expression, “cancer field“ or “tissue organization field” is 
described in the literature. Later, followed by precursor changes, a primary tumor, and recurrence of a tumor or a 
second primary tumor can develop within this field. The behavior of the oral cavity, oropharyngeal, hypopharyn-
geal and laryngeal squamous cell carcinoma can be represented via this model of tumor development17,18.
Micro-RNA
micro RNAs (miRNA) are small, 19–25 mer regulator molecules. Interestingly, miRNAs can behave either as 
oncogenes (oncomirs) or tumor suppressors according to which target mRNA they regulate19,20. The comparison 
of cancer and healthy cells originating from the same tissue presents differences in the expression patterns of 
miRNA. The analysis of the miRNA expression profile proved to be an appropriate method towards differenti-
ating between normal and tumorous tissues, and selecting subgroups specifically in relation to tissue regarding 
several tumorous diseases21. Previous reviews have observed a discrepancy of miRNA findings across studies 
focusing on cancers of the head and neck, and there has been no consensus on specific miRNAs that are associ-
ated to HPV positivity and HNSCC.
In our study, we aimed to analyze the miRNA profile of oropharyngeal squamous cell carcinomas through 
a cancer field model in tumors and surrounding healthy tissues. We collected mapping biopsy series of tissue 
samples from the tumors and from the peritumoral mucosa 1-2-3 cm away from the macroscopic tumor margin. 
We also aimed to visualize the mucosal field and the tumor propagation in 3D model based on radiography and 
to combine it with clinical and genomic results. In our experimental design we selected a set of miRNA targets- 
miR-21-5p, miR-143, miR-155, miR-221-5p- which satisfy the causality criteria for carcinogenesis in HNSCC. 
Considering the behavioral differences of HPV positive and negative oropharyngeal tumors, we investigated the 
miRNA pattern alterations among the two groups with highly quantitative droplet digital PCR technique.
Materials and Methods
Sample collection. Tissue samples (10–60 mg) were collected from patients undergoing surgical inter-
vention and treatment at the Department of Otorhinolaryngology, Head and Neck Surgery, Clinical Center, 
University of Pécs. During our study period between 2017 and 2018, 48 patients were diagnosed and received 
multimodal therapy for oropharynx, hypopharynx and larynx HNSCCs. From this patient cohort 25 patients 
were selected for miRNA analysis based upon the presence of stage T2-3 squamous cell carcinoma of the orophar-
ynx. Tumor classification and clinicopathological evaluation were carried out by a pathology expert according to 
the “8th Edition TNM Classification for Head and Neck Cancer, American Joint Committee on Cancer (AJCC), 
2017”. Clinicopathological staging, HPV P16 immunohistochemistry and HPV genotyping were performed in 
all HNSCC cases. Our sample collection strategy followed a strict scheme towards effectively mapping the biopsy 
originating from the cancer area. We obtained our first sample from the non-necrotic tumor tissue, and next, 
we collected peritumoral macroscopically normal tissue samples at 1 cm, 2 cm and 3 cm distance from the edge 
or perimeter of the tumor. Following collection, tissue samples were snap frozen at −80 °C and stored until pro-
cessing. The clinical and experimental study protocol described here was performed under the license number 
2014/5341 (University of Pécs, regional ethical committee). The methods were carried out in accordance with the 
relevant guidelines and regulations. Informed consent was obtained from all participants who were enrolled in 
this study.
RNA isolation and reverse transcription. Cell free total RNA was isolated from 60 µg fresh frozen tissue 
samples using the Aurum Total RNA mini kit (Cat. no. 7326820; Bio-Rad, Madison, USA). Isolated RNA quality 
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was checked using the Thermo Scientific NanoDropTM 2000 (Thermo Fisher Scientific, Grand Island, NY). 5 ng 
total RNA from each sample was reverse transcribed using the miRCURY LNA Universal RT microRNA PCR Kit 
(Cat. no. 339340; Qiagen).
Droplet digital PCR analysis. Regarding quantitative PCR analysis, we procured the Qiagen miRCury 
LNA miRNA PCR assays (Cat. no. Qiagen, Hilden, Denmark), in accordance with the following miRNA tar-
gets: hsa-miR-21-5p, hsa-miR-143, hsa-miR-155 and hsa-miR-221-5p. Master mixes were prepared to include 
1 µl of miRCury LNA miRNA assay containing the target-miRNA specific forward and reverse primer pair, 
12 µl of QX200 ddPCR EvaGreen Supermix (cat. no. 1864034; Bio-Rad) and 9 µl PCR grade water and 2 µl 
(~100 pg) of cDNA sample. Application onto the plate was perform using approximately 100 pg/µl template 
concentration. Regarding the negative controls, we prepared a master mix, in which the template cDNA 
was substituted with PCR grade water (no template control = NTC and a master mix, in which the template 
cDNA and primer were both substituted with water (no primer control = NTC + NPC). From each master 
mix, droplets were generated in the automated droplet generator unit of the QX200 automated ddPCR sys-
tem using Droplet Generation Oil for EvaGreen (Bio-Rad). PCR amplification was carried out in the QX200 
Thermo cycler with the following thermic conditions (enzyme activation 1 cycle: 95 °C for 5 min; amplifica-
tion 40 cycles {96 °C for 30 s and 58–60 °C -primer dependently-for 1 min}, signal stabilization 1 cycle {4 °C 
for 5 min and 90 °C for 5 min} and hold on, 4 °C. Droplets were immediately analyzed following the PCR 
reaction in the QX200 Droplet Reader. Fluorescence data were converted into concentrations according to 
the Poisson distribution statistical analysis used by the QuantaSoft® Analysis Pro software, version 1.0.596 
(Bio-Rad, CA, USA).
HPV P16 Immunohistochemical staining. At present, HPV association of head and neck SCC is deter-
mined using p16 immunhistochemistry, and it is widely considered as an important marker with respect to 
pathogenesis and prognosis22. Furthermore, the recently published the 8th edition of TNM-staging handbook 
also acknowledged the relevance of differentiating HPV and non-HPV related cases23.
Some consider p16INK4a, the expression of which is thought to be up-regulated due to pRb degradation 
induced by high-risk HPV E7 protein, a marker which is able to identify tumors with relevant viral oncogene 
expression24,25.
All HNSCC cases were evaluated based on FFPE tissue samples using the standard H&E staining and p16 
immunhistochemistry. Regarding the later model, we used the CINtec p16INK4a Detection System (Ref: 9511, 
Roche mtm laboratories AG, Sandhofer Strasse, Mannheim, Germany). The immunostaining was performed 
according to the recommended manufacturer’s protocol.
Additionally, the p16 positive staining was concluded based on the identification of strong nuclear and cyto-
plasmic staining in at least 70% of malignant cells. No staining, faint nuclear and cytoplasmic staining with back-
ground marking, small foci of staining or staining in non-malignant cells were considered negative results. The 
positive control was a cervical squamous cell carcinoma previously proven to be p16 positive, as part of the 
standard clinical laboratory procedure.
DNA extraction and HPV genotyping. 60 µg of fresh frozen tumor tissue sample was used for the 
total DNA extraction using the HighPure template preparation kit (Cat. no. 11796828001; Roche, Molecular 
Diagnostics, Mannheim, Germany). DNA concentration and quality was examined using NanoDrop 
spectrophotometry.
Linear array HPV genotyping test (Cat. no. 04391853 190; Roche Molecular Diagnostics) was used to deter-
mine specifically, which HPV genotypes were present in the tissue samples. The test detects 37 human papilloma-
virus genotypes: 6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 45, 51, 52, 53, 54, 55, 56, 58,59, 61, 62, 64, 66, 67, 68, 69, 70, 
71, 72, 73 (MM9), 81, 82 (MM4), 83 (MM7), 84 (MM8), IS39, and CP610823.
The Linear Array is a qualitative test which uses biotinylated primers sets PGM09/PGMY11 and PC04/GH20 
for simultaneous amplification of a 450 bp and 268 bp fragments of the HPV L1 gene and human beta-globin 
gene, respectively. Following PCR amplification, genotyping is performed using a single nylon strip coated with 
HPV type-specific and human beta-globin-specific oligonucleotide probes26. Testing was performed in accord-
ance with the recommended manufacturer’s instructions.
Statistical analysis. Concentration data acquired from QuantaSoft software (BioRad) were next exported 
and analyzed for quantitative differences between the tissue samples according to histopathology, distance from 
the tumor, and, the location and HPV status were analyzed using IBM SPSS Statistics 21.0 for ANOVA with sta-
tistical significance level p ≤ 0.05.
Image reconstruction for illustration of sample collection sites. CT DICOM data including arterial 
and venous phase contrast-enhanced high resolution series (slice thickness = 0.75 mm, matrix = 512 × 512, pixel 
size = 0.445 mm) of the patient above were converted to nifti format using MRIConvert 2.1.0 (Lewis Center for 
Neuroimaging, University of Oregon, USA) and loaded in 3DSlicer 4.127,28. Based on contrast enhancement, 
anatomy and asymmetry, tumor mass was delineated in axial plane slices by a radiologist using 3DSlicer segment 
editor draw tool. Tumor contours were revised and modified if necessary by a board-certified neuroradiologist 
with over 10 years of clinical experience.
Using the segment editor module of 3DSlicer 4.1 software 3D segmentation of the tumor was created accord-
ing to the delineation. Using the same module, the 3D segmentation of the air inside the pharynx was created 
as well. Using the margin and hollow tools a 1 mm thick boundary was created from the segmentation of the air 
in order to model the mucous membrane. Using the margin tool on the 3D segmentation of the tumor 10 mm, 
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20 mm and 30 mm offset volumes were created according to the sample collection site distances. Using a logical 
operator tool, intersections were created using the segmentations of the mucous membrane and the offset vol-
umes applied to the tumor.
Results
miRNA profile analysis associated with HPV positivity. In the study period our clinical site diagnosed 
48 patients with HNSCC 34 men and 14 women. After clinicopathological classification of the tumors we enrolled 
to this study only the patients with stage T2-3 HNSCCs with oropharyngeal location, based on the “8th Edition 
TNM Classification for Head and Neck Cancer, American Joint Committee on Cancer (AJCC), 2017” (Table 1.)
Out of the 25 mesopharyngeal tumors, eight cases proved to be HPV positive (28%) with p16 immunohisto-
chemical staining (Figs. 1,2). Genotyping found seven cases of HPV 16 positivity and one case with combined 
positivity of HPV 16 and 52 genotypes.
Characteristics
HPV negative 
(n = 17)
HPV positive 
(n = 8)
Total 
(n = 25)
N (%) N (%) N (%)
Gender
Male 13 (52%) 6 (75%) 19 (76%)
Female 4 (23.5%) 2 (25%) 6 (24%)
Age
0–45 — 1 (12,5%) 1 (4%)
45–64 11 (64.7%) 5 (62.5%) 16 (64%)
65+ 6 (24%) 2 (25%) 8 (32%)
Tumor Location
Tonsil 2 (11.8%) 1 (12.5%) 3 (12%)
Base of tongue 6 (24%) 5 (62.5%) 11 (44%)
Oropharyngeal wall 2 (11.8%) — 2 (8%)
Glossotonsillar sulcus 7 (41.2%) 2 (25%) 9 (36%)
Clinical T stage
1 — — —
2 7 (41.2%) 5 (62.5%) 12 (48%)
3 10 (58.8%) 3 (37.5%) 13 (52%)
4 — — —
Clinical N stage
0 3 (17.6%) — 3 (12%)
1 6 (35.2%) 3 (37.5%) 9 (36%)
2 8 (47.1%) 5 (62.5%) 13 (52%)
3 — — —
Overall stage
I — — —
II 3 (17.6%) 4 (50%) 7 (28%)
III 6 (35.2%) 4 (50%) 10 (40%)
IV 8 (47.1%) — 8 (32%)
Risk group
Alcohol 13 (76.5%) — 13 (52%)
Smoking 13 (76.5%) 3 (37.5%) 16 (64%)
Table 1. Demographical and clinical parameters of the selected tumors.
Figure 1. Squamous cell epithelium negative for p16 immunohystochemical staining at 40x magnification. 
Histological section originates from a grade 2 oropharyngeal wall squamous cell carcinoma.
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HPV positive tumor tissues showed higher expression levels of all investigated miRNA compared to the HPV neg-
ative. Significant over expressions in the HPV positive tumor tissue biopsies were found with ANOVA for miR-21-5p 
(F = 5.53, p = 0.022), miR-143 (F = 5.627 p = 0.021), and miR-221-5p (F = 5.065 p = 0.028). The statistical analysis did 
not confirm miR-155 to be consequently correlated to HPV infection in the tissue biopsy series (F = 0.70, p = 0,793). 
Based on our results, we were not able to identity a single miRNA marker specific for HPV positivity, but patterns of the 
miRNA expression profiles correlated with the presence of HPV (Fig. 3.). miRNA expressions in correlation with the 
distance from the tumor margin on the peritumoral mucosa showed patchy pattern alterations of miR-21 and miR-155 
in HPV positive cases, while gradual change of all investigated miRNAs was seen in HPV negative tumors.
Figure 2. Squamous cell epithelium positive for p16 immunohystochemical staining at 40x magnification. 
Histological section originates from a grade 3 tonsillar squamous cell carcinoma.
Figure 3. Comparative heat map analysis of HPV positive and negative tumors. Tissue samples are grouped 
according to HPV positivity and labeled vertically (1 for HPV positive and 0 for HPV negative tissues). The 
horizontal scale shows the mucosal tissue samples according to distance from the macroscopic tumor margin 
(0 = tumor, 1 = normal mucosal tissue 1 cm away from the tumor margin, 2 = normal mucosal tissue from 2 cm 
and 3 = normal mucosal tissue from 3 cm distance from the clinically visible tumor propagation). HPV positive 
and negative tissue sample series were compared on ANOVA for expression differences of miR-21-5p, miR-143, 
miR-155 and miR-221-5p. F-probe results and significance levels are shown on the right side of each heat map. 
The mean difference was accepted to be significant at the 0.05 level.
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miRNA profiles correlating with tissue organization field (TOF). In HPV negative tumors and per-
itumoral tissues miRNA expression changes followed gradual pattern which depended on the measured distance 
from the tumor propagation itself. On the peritumoral normal mucosal field, the gradual concentration decrease 
of two miRNAs (miR-21-5p, miR-221-5p) was found to be statistically significant on the ANOVA test (Fig. 4). 
miR-143 and -155 also showed a similar miRNA distribution pattern, however, it did not reach the limit of sta-
tistical significance.
In the tumors and their neighboring intact mucosa, miR-21-5p showed gradually decreasing values corre-
lating with distance from the tumor propagation. Average miR-21-5p values do not differ significantly among 
the tumor samples and in the 1 cm peritumoral normal mucosa. We found a significant decrease in miR-21-5p 
expression levels in tissues at 2 and 3 cm distance from the tumor margin.
The concentration of miR-221-5p was found to be high in tumor tissues while it decreased rapidly in the 
hystopathologically normal peritumoral mucosa. The standard deviation of the miRNA-221-5p expressions were 
found to scatter in wider range among the tumor biopsies, while we detected more integrated expression levels 
in the mucosa biopsies. Mean miR-221-5p expression levels did not significantly differ from the site of the 1 cm 
peritumoral mucosal region. miR-221-5p levels were equally found to be low in 2 and 3 cm distant biopsies.
Although we noticed gradual down-regulation of miR-143 expression in our cancer field detection model, it 
was not confirmed to be statistically significant on the ANOVA.
Regarding miR-155, we were not able to detect correlation in the mapping biopsy samples with the tumor 
propagation field.
3 Dimensional model. The patient’s HR CT DICOM files were uploaded to 3D slicer version 4.1. The 3D model 
was generated based on a HPV negative right side exulcerated tonsillar tumor (stage T3) with the anatomical 
extension into the vallecula and deeply infiltrating the lateral pharyngeal wall. The area pointed red on the high 
resolution CT shows the primary tumor. It is visualized by 3D slicer program in an anatomical model also appear-
ing with deep orange color (Fig. 5). In this 3D model we were able to visualize the tumor propagation into the 
surrounding mucosal tissues where the biopsy samples were taken from and evaluated for miRNA expression 
levels. On the images the clinical tumor mass is painted deep orange, peritumoral mucosa at 1 cm is inked red, 
2 cm is yellow and 3 cm is green (Figs. 6,7).
Discussion
Growing interest has focused on the development of novel treatment strategies based on HNSCC cell biology. 
Within this trend, recent identification of human papilloma virus (HPV) positive HNSCC is a milestone dis-
covery, because it is has become apparent that this type of cancer has a distinctive genetic and epigenetic profile, 
which can be cured within the framework of conventional organ-preserving treatment29–33.
HPV genotyping experiments, have demonstrated that HPV 16 has the highest percentage in oropharyngeal 
tumors and in a smaller proportion, the presence of HPV 33 and 35 genotypes have also been confirmed34. In our 
study we applied a genotyping platform which is able to recognize a broad spectrum of mucosal HPV genotypes.
We could confirm HPV 16 as the most frequent genotype in all our clinical samples (7 cases out of 48) and we 
also detected HPV 52 besides HPV 16 in a single case. HPV 52 belongs to the high cancer inducing risk category 
Figure 4. Micro-RNA expression values (y axis: absolute quantification results in copy/μl) according to 
distance of the biopsy sample from the macroscopic tumor margin (row: 0: tumor, 1: 1 cm from the tumor, 
2: 2 cm from the tumor, 3: 3 cm from the tumor). The mean differences were analyzed with ANOVA and 
significance was maintained at the 0.05 level.
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(HR) HPV group and it was found to be the third most prevalent genotype- after HPV 42 and HPV 16- during 
the routine cervical HPV genotyping at our laboratory site. In the head and neck region the oropharynx pre-
sents the highest ratio of HPV associated HNSCC. The mucosal surface of lacunas and crypts constitute a strong 
conjunction between the epithelial mucosa and the lymphatic tissue underneath and is often revealed in the 
background of tonsillar predilection of HPV initiated carcinogenesis. During our study period between 2017 and 
2018, 48 patients were diagnosed with oropharynx, hypopharynx and larynx HNSCCs. From this patient cohort 
25 patients had orophyaryngeal tumor and were selected into the study for HPV genotyping and microRNA 
expression characterization. Due to the very prospective manner of the study (the patients were diagnosed, than 
mapping biopsy was carried out and biopsies was analyzed for HPV with other genetic features of the samples) 
whilst we gained HPV negative and HPV positive case numbers according to the general HPV incidence in our 
region. Although the quantity of HPV positive samples used in our statistical analysis restrict the interpretation 
of our results due to its smaller number compared to the HPV negative tumors (8 HPV positive cases compared 
to 17 cases of HPV negatives in the T2-3 stage oropharyngeal HNSCCs). To fulfill the need for group equalizing 
we should have waited a two-year period to be able to complete sample size for HPV positive tumor group. Since 
our study is a proof of concept for the 3D model combined with miRNA expression analysis we presume that case 
number would not influence much on the outcome. Also it is hard to reflect the current results on HPV positivity 
of the HNSCCs found in our region, because it is known that geographic distribution and the prevalence of cer-
tain HPV genotypes may differ, which can cause differences in tumor induction.
The molecular pathways of viral and chemical carcinogenesis are different resulting in alterations in miRNA 
profiles35. In our study we found differences in miRNA expression patterns in the HPV positive and negative 
tumor tissues as well as in the surrounding mucosal fields.
Figure 5. HR CT image and 3D model of a HPV negative stage T3 tonsillar squamous cell carcinoma. Tumor 
mass is marked red on the horizontal, sagittal and frontal planes in all sections and a 3D model is built up based 
on the CT segments on the upper right quarter of the picture.
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We found miR-21-5p expression to reach higher levels in HPV positive tumors and 1 cm distant peritumoral 
area. In study evidences published so far, miR-21 showed significantly lower expression in HPV positive head and 
neck tumors, compared to HPV negative ones36–38. However, these studies lacked the clinical and histopatholog-
ical homogeneity of their samples. Sample enrollment was heterogenic for the clinical stage. Furthermore, tumor 
negative samples were collected close to the tumor itself; consequently, these studies neglected to take in consider-
ation the tumor organization field. Our study samples were all taken from homogeneous, advanced stage (T2, T3) 
tumor propagations for both HPV negative and positive tumors, so our results reflect miR-21-5p characteristics 
of clinicopathologically homogenous tumor groups. Our tumor negative samples were collected according to a 
complete mapping biopsy strategy taking into consideration the TOF (tissue organization field).
Figure 6. 3D image of HPV negative stage T3 right side exulcerated tonsillar squamous cell cancer - with 
the anatomical extension into the vallecula and infiltrating the lateral pharyngeal wall (deep orange)- and 
peritumoral mucosa at 1 cm from the tumor margin (red tone), at 2 cm (yellow) and 3 cm (green) from the 
tumor margin in sagittal view.
Figure 7. 3D image of HPV negative stage T3 right side exulcerated tonsillar squamous cell cancer - with 
the anatomical extension into the vallecula and infiltrating the lateral pharyngeal wall (deep orange)- and 
peritumoral mucosa at 1 cm from the tumor margin (red tone), at 2 cm (yellow) and 3 cm (green) from the 
tumor margin in frontal view.
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miR-143 is a tumor suppressor miRNA, which has been identified as having a lower expression level in HPV 
associated head and neck tumors. It inhibits the proteins E2F (E2 transcription factor) and survivin and their 
protein translation, which contributes to tumor proliferation and neoangiogenesis39. It is associated with a better 
prognosis, hence its higher expression was observed in HPV positive oropharyngeal tumors40. We have also found 
a high miR-143 expression in HPV positive tumors compared to the negatives, but the difference was more char-
acteristic for the peritumoral mucosa, which showed significantly higher concentrations of miR-143.
As well as miR-21-5p, we recognized miR-221-5p with significantly higher expression levels in the HPV pos-
itive cancers compared to the negatives, which may also be explained by the fact that HPV positive tumors were 
large in size. On our mapping biopsy evaluation the highest miRNA values were measured for the HPV positive 
tumor tissues and miR-221-5p expression. In conclusion, our findings confirm that miR-221 is involved in HPV 
positive HNSCC tumor growth.
Regarding the HPV negative HNSCCs despite the exponentially expanding information on the cellular biol-
ogy, research evidence has not lead to a holistic understanding of the dynamically evolving molecular circuitry 
of this type33. Many factors seem to contribute to their development, such as the accumulation of genetic and 
epigenetic alterations, e.g. chromosomal abnormalities, inactivation of tumor suppressors, and increased activity 
of oncogenes. Signaling pathways in antitumor mechanisms are involved in tumor initiation and progression cor-
relating with biological aggressiveness: TP53 (tumor protein p53), RB1/INK4/ARF (retinoblastoma-associated 
protein 1/infestin 4/alternate open reading frame) and NOTCH1 (neurogenic locus homolog protein 1) signa-
ling pathways are recognized. Data from DNA sequence analysis implies that the phosphatidylinositol 3-kinase 
PI3K-Akt-mTOR pathway is also frequently involved in the cancer development41.
Recent rapid progress in epigenetic approach has revealed that noncoding RNAs (ncRNA), especially miRNA, 
have a fine-tuner role within gene transcription. Through interaction with mRNA and chromatin modulators, 
miRNA orchestrates the stoichiometric equilibrium of gene expression on dynamically changing cellular con-
text33. Thereby, miRNA behaves as a morphostatic factor, linking epigenetic to genetic factors, it is characterized 
by distinct genetic attributes and plays a key role in the regulation of the mucosal landscape and has been proven 
to be useful in the molecular characterization of several tumor types41. In our study, we utilized the benefits of this 
molecule to detect and characterize the HNSCC tissue organization field. Considering the quantitative differences 
in the miRNA expression, we found many alterations between tumors and phenotypically intact tissues at defined 
distances. We revealed significant changes of miR-21-5p and miR-221-5p in HPV negative tumors. Tumor sur-
rounding normal mucosa showed gradual concentration depletion of these markers.
In previous studies, the role of miR-21 has been demonstrated in the inhibition of protein translation of the 
mRNA of the p53 gene responsible for cell cycle regulation in malignant melanoma and oral squamous cell 
carcinoma42. An elevated expression of miR-21 was also reported in squamous cell carcinomas of the head and 
neck43,44, including larynx45, pharynx and tongue tumors, primarily metastatic squamous cell carcinomas of the 
tongue in the latter46. The increased expression of miR-21 is closely related to a low five-year survival rate and 
lower response to chemoradiotherapy, which can be an important tool for treatment planning and prognosis esti-
mation in the future36,37. Currently, there is no evidence in relation to mapping biopsy in literature, but during the 
progress of our examinations, we found high values of miR-21-5p in the healthy tissue at a distance of 1 cm from 
the tumor, which correlates with the surgical safety zone.
miR-155 is a type of miRNA, identified in squamous cell cancers of the larynx, it promotes tumor invasion by 
blocking the SOC (suppressor of cytokine signaling proteins) and STAT (signal transducer and activator of tran-
scription) transcription factors47. It can be closely associated with a local recurrence in the case of oropharyngeal 
cancer48, and its expression is higher in laryngeal tumors49. It also correlates with tumor proliferation, tendency 
for metastasis and poor prognosis50–53. The changes in biomarker values in miR-155, measured at different biopsy 
distances, could not prove the role of miR-155 in the peritumoral field in our study.
A previous study by Hussein et al. confirmed decreased miR-143 expression within the HNSCC tumor tissue, 
compared to the values measured in the mucosal controls54,55. In our study, we found a higher expression in 
tumor samples than in normal tissue, however the tissues taken at 1 cm distance in the intact mucosa showed sim-
ilar, and in some cases higher expression levels compared to the tumor samples themselves. Changes were found 
to be very moderate. The expression results decreased with the distance in the peritumoral field.
High expression of miR-221 has been demonstrated by several previous studies in the case of laryngeal squa-
mous cell carcinoma56 and head and neck squamous cell carcinoma57, while low expression has been reported in 
tumor-free tissue. We can confirm these results for miR-221-5p as our tissue organization field model, showed a 
significant gradual change on the tumor surrounding mucosal surface.
Overall, it can be said that the differing patterns of HPV positive tumors can explain the prognostic and 
behavioral differences compared to HPV negative tumors. In order to perform a comprehensive examination 
regarding epigenetic differences, additional investigations are needed with more cases involved. We plan to exam-
ine regulation of the miRNAs, we have analyzed thus far, through their target mRNAs in a future research project.
In the CT based 3 D model we tried to visualize the tumor mass and the peritumoral tissues considering 
our mapping biopsy strategy and the tissue miRNA expression results. In the 3D model the clinical tumor mass 
and the peritumoral tissue locating at 1 cm distance from the macroscopically tumorous margin - where similar 
miRNA patterns were proved - presents in red tone colors with precise compilation (Figs. 6,7). Surgical excision 
carried out in this zone can result a high risk of tumor recurrence. Yellow color represents peritumoral tissue at 
2 cm distance from the tumor margin. This is a safety field with a better epigenetic patterns differing from the 
tumor. In case of resecable tumors the surgical resection is highly recommended in this area to avoid the locore-
gional recurrence. This model can be utilized in preoperative surgical planning to decide the optimal tumor 
resection line. In case the surgical line affects the functionality (swallowing, breathing and speaking) we prefer 
the organ preservation among therapeutical modalities (chemoirradiation). The 3D software might be effective in 
assisting preoperative planning, especially in current clinical settings. Our approach enables the risk estimation 
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of malignant disease progression before the operative intervention on the basis of genomic and epigenetic char-
acteristics of the tumor and the peritumoral mucosal surface and the surgical safety margin can be determined in 
consideration with the anatomical situation of the mucosal landscape. This strategy could facilitate the complex 
planning of surgical excision. In some cases, where the anatomy does not permit a more extended surgery accord-
ing to the 3D model and tumor removal was carried out in the 1 cm zone which is still histologically tumor-free 
but high recurrence risk is indicated by genomic evaluation a closer patient follow-up is highly recommended.
HPV positive cases, where organ preservation and chemo-irradiation therapy are usually preferred, could also 
be managed in a more precise way based on the 3D models and genomic cancer field evaluation.
Our ultimate goal was to optimize the diagnostic steps in HNSCC management, to estimate and minimalize 
the chances of tumor recurrence and to achieve better survival with higher life quality of HNSCC patients.
Ethics approval and consent to participate. The clinical and experimental study protocol described 
here was performed under the license number 2014/5341 (University of Pécs, regional ethical committee). The 
methods were carried out in accordance with the relevant guidelines and regulations. Informed consent was 
obtained from all participants who were enrolled in this study.
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